Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

@article{Furuta2005InfluenceOC,
  title={Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.},
  author={T Furuta and Naohito Shirai and M Sugimoto and Akiko Nakamura and Akira Hishida and Takashi Ishizaki},
  journal={Drug metabolism and pharmacokinetics},
  year={2005},
  volume={20 3},
  pages={153-67}
}
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are mainly metabolized by CYP2C19 in the liver. There are genetically determined differences in the activity of this enzyme. The genotypes of CYP2C19 are classified into the three groups, rapid extensive metabolizer (RM), intermediate metabolizer (IM), and poor metabolizer (PM). The pharmacokinetics and pharmacodynamics of PPIs depend on CYP2C19 genotype status. Plasma PPI levels and… CONTINUE READING